Health Care·Biotechnology·$10.3B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.30 | N/A | -129.16% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.30 | N/A | -129.16% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current financial performance and reiterated their commitment to research and development. They did not provide specific guidance for future quarters.
Management highlighted ongoing challenges in achieving profitability.
They emphasized the need for continued investment in R&D to support future growth.
No specific updates were provided regarding product launches or pipeline progress.
BioMarin Pharmaceuticals reported a loss per share that was significantly worse than expected, which contributed to a slight decline in stock price. The lack of revenue details and forward guidance may raise concerns among investors about the company's near-term prospects. The stock's minor drop of 0.25% reflects cautious sentiment in light of these results.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
VERISK ANALYTICS INC A
Feb 20, 2018